查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1698085

肾癌药物市场－全球产业规模、份额、趋势、机会及预测（依治疗类别、药理类别、地区及竞争情形划分，2020-2030 年预测）

Kidney Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutic Class, By Pharmacologic Class, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球肾癌药物市场价值为 71.5 亿美元，预计在预测期内将呈现强劲成长，到 2030 年的复合年增长率为 6.45%。肾癌，也称为肾细胞癌，是一种起源于肾臟的癌症，肾臟是一种豆形器官，负责过滤血液中的废物和多余的液体以形成尿液。肾癌，医学上称为肾细胞癌 (RCC)，是一种复杂且具有挑战性的疾病，需要有效的治疗策略。随着医学研究的进步和药物创新的加速，几个关键驱动因素正在推动肾癌药物市场的成长和发展。标靶治疗是一类旨在抑制对癌细胞生长和存活至关重要的特定分子或途径的药物。对于肾臟癌而言，标靶治疗彻底改变了治疗方法。例子包括酪胺酸激酶抑制剂 (TKI)，如舒尼替尼、帕唑帕尼和阿昔替尼。这些药物会破坏促进肿瘤生长和血管生成（新血管形成）的讯号路径。这些药物的引入极大地改变了肾癌治疗的模式。曾经面临有限选择的患者现在可以获得一系列可提高生存率和生活品质的治疗方法。随着研究的不断深入，肾癌药物市场将迎来进一步的发展。联合疗法、个人化医疗方法以及新目标的整合即将出现。此外，研究人员、製药公司、医疗保健组织和患者权益团体之间的持续合作将继续影响创新疗法的发展，并最终为肾癌患者带来更好的治疗效果。

市场概览
预测期 2026-2030
2024 年市场规模 71.5 亿美元
2030年市场规模 104.3 亿美元
2025-2030 年复合年增长率 6.45％
成长最快的领域 标靶治疗
最大的市场 北美洲

主要市场驱动因素

肾癌发生率上升

主要市场挑战

抗药性和治疗异质性

主要市场趋势

个人化医疗革命

目录

第 1 章：产品概述

第 2 章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球肾癌药物市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依治疗类别（标靶治疗、免疫疗法、化疗）
    • 依药理类别（血管新生抑制剂、单株抗体、mTOR 抑制剂、细胞激素免疫疗法 (IL-2)）
    • 按公司分类（2024）
    • 按地区
  • 市场地图

第六章：北美肾癌药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 墨西哥
    • 加拿大

第七章：欧洲肾癌药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太肾癌药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 印度
    • 韩国
    • 日本
    • 澳洲

第九章：南美肾癌药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第十章：中东和非洲肾癌药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 合併与收购

第 13 章： 大环境分析

第 14 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章：竞争格局

  • Novartis AG
  • Pfizer Inc.
  • Bayer AG
  • Genentech Inc.
  • Bristol-Myers Squibb
  • Eisai Co., Ltd.
  • Exelixis Inc
  • Prometheus Laboratories Inc
  • Glaxosmithkline PLC.
  • F. Hoffmann-LA Roche AG

第 16 章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 17209

Global Kidney Cancer Drugs Market was valued at USD 7.15 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.45% through 2030. Kidney cancer, also known as renal cell carcinoma, is a type of cancer that originates in the kidneys, the bean-shaped organs responsible for filtering waste and excess fluids from the blood to form urine. Kidney cancer, medically termed renal cell carcinoma (RCC), is a complex and challenging disease that demands effective treatment strategies. As medical research advances and pharmaceutical innovation accelerates, several key drivers are propelling the growth and evolution of the kidney cancer drugs market. Targeted therapies are a class of drugs designed to inhibit specific molecules or pathways that are crucial for cancer cell growth and survival. In kidney cancer, targeted therapies have revolutionized treatment. Examples include tyrosine kinase inhibitors (TKIs) such as sunitinib, pazopanib, and axitinib. These drugs disrupt the signaling pathways that promote tumor growth and angiogenesis (formation of new blood vessels). The landscape of kidney cancer treatment has been dramatically transformed by the introduction of these drugs. Patients who once faced limited options now have access to a range of therapies that offer improved survival rates and enhanced quality of life. As research continues, the kidney cancer drugs market is poised for further advancements. Combination therapies, personalized medicine approaches, and the integration of novel targets are on the horizon. Additionally, the ongoing collaboration among researchers, pharmaceutical companies, healthcare organizations, and patient advocacy groups will continue to shape the development of innovative therapies and ultimately lead to better outcomes for patients facing kidney cancer.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.15 Billion
Market Size 2030USD 10.43 Billion
CAGR 2025-20306.45%
Fastest Growing SegmentTargeted Therapy
Largest MarketNorth America

Key Market Drivers

Rising Incidence of Kidney Cancer

The global kidney cancer market is experiencing significant expansion, largely driven by the rising incidence of kidney cancer worldwide. In 2022, kidney cancer accounted for 434,840 newly diagnosed cases globally, making it the 14th most prevalent cancer worldwide. It ranked as the 10th most diagnosed cancer among men and the 13th among women, underscoring its significant impact on global healthcare systems and oncology markets. The increasing number of renal cell carcinoma (RCC) cases-the most common type of kidney cancer-has created a growing demand for advanced diagnostics, innovative therapeutics, and improved healthcare infrastructure. This trend is not only shaping market dynamics but also influencing the strategic direction of pharmaceutical companies, healthcare providers, and investors. The global population is aging at an unprecedented rate. Between 1974 and 2024, the proportion of individuals aged 65 and older nearly doubled, rising from 5.5% to 10.3%, and age is a significant risk factor for kidney cancer. With higher life expectancy, the number of kidney cancer cases is expected to increase, driving demand for effective treatment options. Developed regions such as North America and Europe report higher incidence rates due to advanced screening programs and improved diagnostic capabilities. Meanwhile, emerging economies in Asia-Pacific are seeing rising cases due to lifestyle changes and increasing industrialization, leading to a higher demand for cancer therapeutics.

Key Market Challenges

Resistance and Treatment Heterogeneity

Despite the advancements in targeted therapies and immunotherapies, the development of resistance to these treatments remains a significant challenge in kidney cancer. Over time, tumors can evolve and adapt, rendering once-effective therapies ineffective. This challenge underscores the need for continuous research to understand the mechanisms of resistance and develop strategies to overcome it. Additionally, kidney cancer is not a homogeneous disease. Different subtypes and genetic variations contribute to variations in treatment response. Developing therapies that are effective across diverse patient populations is a complex endeavor that requires a deep understanding of tumor biology and personalized medicine approaches.

Key Market Trends

Personalized Medicine Revolution

The era of personalized medicine has dawned upon the field of kidney cancer treatment, offering immense promise for improved patient outcomes. With the advent of precision oncology, the one-size-fits-all approach to treatment is giving way to tailored interventions that account for individual genetic profiles and biomarker expression. Advancements in genomics and molecular diagnostics enable oncologists to identify specific genetic mutations or alterations driving a patient's kidney cancer. Armed with this information, they can prescribe targeted therapies that are more likely to elicit a favorable response. This shift towards personalized treatment approaches not only enhances the efficacy of drugs but also minimizes the potential for adverse effects.

Key Market Players

  • Novartis AG
  • Pfizer Inc.
  • Bayer AG
  • Genentech Inc.
  • Bristol-Myers Squibb
  • Eisai Co., Ltd.
  • Exelixis Inc
  • Prometheus Laboratories Inc
  • Glaxosmithkline PLC.
  • F. Hoffmann-LA Roche AG

Report Scope:

In this report, the Global Kidney Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Kidney Cancer Drugs Market, By Therapeutic Class:

  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy

Kidney Cancer Drugs Market, By Pharmacologic Class:

  • Angiogenesis Inhibitors
  • Monoclonal Antibodies
  • mTOR Inhibitors
  • Cytokine Immunotherapy (IL-2)

Kidney Cancer Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Kidney Cancer Drugs Market.

Available Customizations:

Global Kidney Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Kidney Cancer Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutic Class (Targeted Therapy, Immunotherapy, Chemotherapy)
    • 5.2.2. By Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy (IL-2))
    • 5.2.3. By Company (2024)
    • 5.2.4. By Region
  • 5.3. Market Map

6. North America Kidney Cancer Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutic Class
    • 6.2.2. By Pharmacologic Class
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Kidney Cancer Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapeutic Class
        • 6.3.1.2.2. By Pharmacologic Class
    • 6.3.2. Mexico Kidney Cancer Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapeutic Class
        • 6.3.2.2.2. By Pharmacologic Class
    • 6.3.3. Canada Kidney Cancer Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapeutic Class
        • 6.3.3.2.2. By Pharmacologic Class

7. Europe Kidney Cancer Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutic Class
    • 7.2.2. By Pharmacologic Class
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Kidney Cancer Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutic Class
        • 7.3.1.2.2. By Pharmacologic Class
    • 7.3.2. Germany Kidney Cancer Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutic Class
        • 7.3.2.2.2. By Pharmacologic Class
    • 7.3.3. United Kingdom Kidney Cancer Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutic Class
        • 7.3.3.2.2. By Pharmacologic Class
    • 7.3.4. Italy Kidney Cancer Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapeutic Class
        • 7.3.4.2.2. By Pharmacologic Class
    • 7.3.5. Spain Kidney Cancer Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapeutic Class
        • 7.3.5.2.2. By Pharmacologic Class

8. Asia-Pacific Kidney Cancer Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutic Class
    • 8.2.2. By Pharmacologic Class
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Kidney Cancer Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutic Class
        • 8.3.1.2.2. By Pharmacologic Class
    • 8.3.2. India Kidney Cancer Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutic Class
        • 8.3.2.2.2. By Pharmacologic Class
    • 8.3.3. South Korea Kidney Cancer Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutic Class
        • 8.3.3.2.2. By Pharmacologic Class
    • 8.3.4. Japan Kidney Cancer Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutic Class
        • 8.3.4.2.2. By Pharmacologic Class
    • 8.3.5. Australia Kidney Cancer Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutic Class
        • 8.3.5.2.2. By Pharmacologic Class

9. South America Kidney Cancer Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutic Class
    • 9.2.2. By Pharmacologic Class
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Kidney Cancer Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutic Class
        • 9.3.1.2.2. By Pharmacologic Class
    • 9.3.2. Argentina Kidney Cancer Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutic Class
        • 9.3.2.2.2. By Pharmacologic Class
    • 9.3.3. Colombia Kidney Cancer Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutic Class
        • 9.3.3.2.2. By Pharmacologic Class

10. Middle East and Africa Kidney Cancer Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutic Class
    • 10.2.2. By Pharmacologic Class
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Kidney Cancer Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutic Class
        • 10.3.1.2.2. By Pharmacologic Class
    • 10.3.2. Saudi Arabia Kidney Cancer Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutic Class
        • 10.3.2.2.2. By Pharmacologic Class
    • 10.3.3. UAE Kidney Cancer Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutic Class
        • 10.3.3.2.2. By Pharmacologic Class

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Product & Service Offerings
    • 15.1.3. Recent Developments
    • 15.1.4. Financials (If Listed)
    • 15.1.5. Key Personnel
    • 15.1.6. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Bayer AG
  • 15.4. Genentech Inc.
  • 15.5. Bristol-Myers Squibb
  • 15.6. Eisai Co., Ltd.
  • 15.7. Exelixis Inc
  • 15.8. Prometheus Laboratories Inc
  • 15.9. Glaxosmithkline PLC.
  • 15.10. F. Hoffmann-LA Roche AG

16. Strategic Recommendations

17. About Us & Disclaimer